Durvalumab Plus Chemotherapy Improves Survival in Advanced Biliary Tract Cancer
Treatment with the PD-L1 inhibitor durvalumab in combination with gemcitabine and cisplatin resulted in significantly improved overall survival vs placebo plus chemotherapy in patients with advanced biliary tract cancer. Treatment with the PD-L1 inhibitor durvalumab (Imfinzi) in combination with gemcitabine and cisplatin resulted in significantly improved overall survival (OS)...
www.onclive.com
Comments / 0